研究課題/領域番号 |
21K08152
|
研究種目 |
基盤研究(C)
|
配分区分 | 基金 |
応募区分 | 一般 |
審査区分 |
小区分53030:呼吸器内科学関連
|
研究機関 | 名古屋大学 |
研究代表者 |
コーチン ビタリー 名古屋大学, 医学系研究科, 特任助教 (30648001)
|
研究期間 (年度) |
2021-04-01 – 2024-03-31
|
研究課題ステータス |
交付 (2022年度)
|
配分額 *注記 |
4,030千円 (直接経費: 3,100千円、間接経費: 930千円)
2023年度: 1,170千円 (直接経費: 900千円、間接経費: 270千円)
2022年度: 1,430千円 (直接経費: 1,100千円、間接経費: 330千円)
2021年度: 1,430千円 (直接経費: 1,100千円、間接経費: 330千円)
|
キーワード | GPRC5A / irAEs, / ICIs / autoimmune Ab / cytotoxic T cells / irAEs / Autoimmune antibody / Cytotoxic T cells / Lung-related irAEs / Immune checkpoint |
研究開始時の研究の概要 |
We are trying to elucidate the mechanisms that drive the immune-mediated recognition and killing of cancer cells as well as autoimmune damage to normal/healthy cells (immune-related adverse events, irAEs) by cytotoxic T lymphocytes activated upon immune checkpoint inhibitor (ICI) therapy. Understanding the mechanisms that underlie the development of the irAE-based autoimmune lung damage in ICI-treated patients will shed light on the ways to improve immunotherapy efficiency and for better managing of irAEs.
|
研究実績の概要 |
Immune Related Adverse Events (irAEs) restrain ICIs use. The irAEs are caused by ICI-induced autoimmunity against self-tissues by auto-antibody (Ab) or self-reacting T cells. We found GPRC5A-derived peptide epitope presented by HLA-A24 specifically in human lung cells and currently investigating whether autoreactive T cells and/or Ab to GPRC5A may be responsible for the inflammation and damage in lung tissue of patients who underwent treatment with ICIs. We use HLA-A24 transgenic MHC-KO mice (A24-Tg mice) as a model. We have confirmed that the lung tissue of the A24-Tg animals express HLA-A24 and can process and present GPRC5A-derived peptide epitope identical to the one in human cells.
|
現在までの達成度 (区分) |
現在までの達成度 (区分)
2: おおむね順調に進展している
理由
The objective of the second year (2022-2023) was successfully completed by the generation of the homozygous A24-Tg mice. We applied the previously developed protocol to induce CTLs against a model peptide antigen (ovalbumin) in the homozygous A24-Tg mice setting. We were able to show that ovalbumin peptides can be presented in HLA-A24-restricted manner in our homozygous A24-Tg animals confirming the feasibility of the immunization approach to induce and assay the peptide/MHC-restricted cytotoxic T cells (CTLs) using ELISpot. However, induction of self-reacting CTLs using immunization with self-GPRC5A peptide still remains a challenge.
|
今後の研究の推進方策 |
Currently we are trying to immunize homozygous A24-Tg mice treated with ICIs to mimic patients' treatment conditions. We are using murine GPRC5A synthetic peptide in conjunction with the Freund's adjuvant for immunization along with anti-PD-1 Ab injections. We may use another adjuvant setting if induction of self-reacting CTLs using current protocol doesn’t show significant progress. Upon induction of self-reactive cellular immune response in HLA-A24-Tg MHC-KO mice we are going to probe whether such induced CTLs attack HLA-A24-expressing lung tissue causing inflammation and damage similar to irAEs in patients.
|